00241 ALI HEALTH
- 3.570
- +0.180+5.31%
ALI HEALTH News
Hong Kong Shares Rebound 2.9% Amid Positive Sentiment
Hong Kong's Hang Seng Index extended early gains to close 2.9% higher at 18430.39. There could be some optimism among investors that more may be done by the Chinese authorities in 2H, IG market strate
Hong Kong stocks abnormality | Ali Health (00241) rose more than 4%, 2024 fiscal year performance exceeded expectations, Goldman Sachs pointed out that its profit margin visibility is high.
According to the Finance and Economics APP, the ali health (00241) has risen by over 4%, reaching 4.13% at the time of publication, with a trading volume of 90.3826 million Hong Kong dollars. On the news, ali health's revenue for the period ending in March 2024 was 27.027 billion yuan; net income was 883 million yuan, up 64.6% year-on-year, and adjusted net income was about 1.438 billion yuan, up 90.8% year-on-year. Haitong International believes that the company's profits exceed market expectations, and the profit margin for the fiscal year 2025 is expected to further improve. In terms of internet plus-related services online and offline, prescription outflow, and online medical insurance policies.
Goldman Sachs reaffirms their "buy" rating for Ali Health (00241), with a target price of HKD 4.4.
Goldman Sachs believes that ali health's profit margin will be visible in the next two years.
Ali Health (00241) granted a total of 3,700,700 stock options and 73,600,600 restricted stock units.
Alibaba Health (00241) announced that on June 14th, 2024, the company granted a total of 3.7007 million subscription rights and a total of 73.6006 million restricted share units to 2 affiliated grantors according to the terms of the share incentive plan, and must wait for acceptance before becoming effective for 576 grantees.
Hong Kong Stock Market News: Ali Health (00241) rose more than 7%, with full-year performance exceeding market expectations. The company's business scale effect is expected to continue to expand.
Ali Health (00241) has risen by more than 7% again, with a cumulative increase of more than 20% after the performance. As of press time, it has risen by 6.2%, to HKD 3.77, with a turnover of HKD 248 million.
Hang Seng Index Likely to Consolidate Between 18500-20000 Near Term
0642 GMT - Hong Kong's Hang Seng Index is likely to consolidate between 18500 and 20000 in the near term, according to CCB International analysts Cliff Zhao and Wilson Zou in a research note. They say
Brokerage Focus: Haitong Int'l maintains a "outperform" rating on Ali Health (00241), indicating that its business scale effect is expected to continue to expand.
Haitong International released a research report stating that Ali Health (00241) has released its 2024 fiscal year performance announcement, achieving a revenue of 27.03 billion yuan (+1.0%) and a net income of 880 million yuan (+64.6%), with a corresponding net margin of 3.3% (+1.3pct), achieving an adjusted net income of about 1.44 billion yuan (+90.8%). The company's revenue and profits exceeded market expectations, with rapid growth in health care products and medical instruments, steady improvement in gross margin, and significant optimization of operating cost ratio. The bank believes that as the penetration rate of online and offline services in the internet plus-related field continues to increase and prescription outflow continues to improve.
Citi: Maintaining Ali Health's (00241) “Buy” Rating Target Price Raised to HK$4.2
Citi raised Alibaba Health's (00241) net profit forecast for the 2025 and 2026 fiscal years by 91% and 81%, respectively.
[Special Offer V] Deng Shengxing: Oil Group agreed to cut production until the end of 2025, oil prices will remain high
Jinwu Financial News | The Hang Seng Index closed at 18079 on Friday (31st), down 150 points or 0.83%. The daily turnover was 191,751 billion yuan. The national index closed down 1.1% to 6392. The index fell 1.65% to 3690. Tencent (00700) fell 2.2% to 359.8 yuan, with the highest turnover of 14.675 billion yuan. Meituan (03690) added 3.5% to report 105.1 yuan. China Mobile (00941) increased 2.5%, making it the blue-chip with the best full-day performance. After rising for four days, Ali Health (00241) plummeted 8.6%, making it the worst performing blue chip. Dow Friday (3
CICC: Maintaining Ali Health's (00241) “Outperform the Industry” rating target price of HK$4.2
The Zhitong Finance App learned that CICC released a research report stating that it maintained the “outperforming industry” rating of Ali Health (00241), raised the 2025 FY profit forecast by 76.3% to 1.38 billion yuan, and introduced the 2026 FY profit forecast of 1.62 billion yuan for the first time, considering that the company's cost side narrowed and exceeded expectations. Considering the volatile overall valuation of the sector, the target price is HK$4.2. The company announced 2024FY results: revenue of 27.027 billion yuan (+1.0% YoY), net profit of 883 million yuan (+64.9% YoY), adjusted net profit of 1,438 million yuan (+9)
[Broker Focus] SPDB International maintains Ali Health (00241) “holding” rating indicates that FY25 net profit is expected to maintain a high growth rate
Jinwu Financial News | SPDB International Development Research Report shows that Alibaba Health (00241) FY24 revenue/adjusted net profit was +1%/+91%, respectively. Affected by the high sales base of pandemic-related products in the same period last year, the revenue growth rate was relatively flat. However, during the fiscal year, the company effectively controlled the fulfillment fee rate, which led to a strong increase in adjusted net profit that exceeded expectations. The company guided FY25 revenue growth rate of at least 15%, and the net interest rate increased to about 5 pcts (corresponding net profit growth rate of about +76%). According to the bank, the company's revenue growth improved in April-May, and the bank expects to see more clearly the revenue growth recovery data in the interim report. Based on 1
Alibaba Health Information Technology's Net Profit May Surge -- Market Talk
0645 GMT - Alibaba Health Information Technology is likely to see its net profit surge in the next two years, according to Citi analysts led by John Yung in a research note. Management guided net prof
Alibaba Health Information Technology Target Price Raised to HK$9.50 From HK$8.00 by Citi>0241.HK
Alibaba Health Information Technology Target Price Raised to HK$9.50 From HK$8.00 by Citi>0241.HK
Despite slow growth, Ali Health is gradually becoming “healthy”
Jinwu Financial News | On May 27, Alibaba Health (00241.HK) announced its annual results for the 2024 fiscal year ending March 31, 2024. During the reporting period, it achieved revenue of 27.027 billion yuan, a slight increase of 1.0% year on year, and realized net profit of 883 million yuan, an increase of 64.6% year on year, with a significant increase in profit against the backdrop of flat revenue growth. The number of members of over 77 million and a MAU of up to 300 million have made Ali Health's current earnings report very popular. Driven by the results, Alibaba Health Hong Kong stock surged 10% on the 28th.
Changes in Hong Kong stocks | Alibaba Health (00241) rose more than 4%, annual results beat expectations, institutions expect profit growth to accelerate in FY2025
The Zhitong Finance App learned that Ali Health (00241) rose by more than 4%. As of press release, it rose 4.14% to HK$3.52, with a turnover of HK$200 million. According to the news, Ali Health announced its annual results for the year ended March 31, 2024, with total revenue of 27.026.6 billion yuan; gross profit of about 5.895 billion yuan, an increase of 3.4% over the previous year. Net profit reached 883 million yuan, a year-on-year increase of 64.6%. The adjusted net profit was approximately $1,438 million, an increase of 90.8% over the previous year. Bank of America Securities pointed out that the company's performance for the full year ended at the end of March was better than expected, and revenue trends in major business segments
[Special Offer V] Deng Shengxing: Hong Kong stock market recovery suggests focusing on power grid stocks
Jinwu Financial News | The Hang Seng Index closed at 18821 on Tuesday (28th), down 6 points. Full-day transactions amounted to $97.764 billion; the national index rose 82 points, or 1.25%, to 6,688 points. The national index fell 2 points to 6686. The stock index fell 0.3% to 3854. The mainland stock market declined at the end of the year, and the market closed with a 1.2% drop in poor performance. Yingfu (02800) rose 0.1% to 19.02 yuan, with the highest turnover of 6.939 billion yuan. The second-largest transaction was Tencent (00700), which rose 0.7% to 380.2 yuan. Online medical stocks are doing well, and Ali Health (00241) is pure throughout the year
Citibank: Target price of HK$8 for the “buy” rating for Ali Health (00241)
Ali Health (00241)'s revenue for the 2024 fiscal year ending the end of March this year exceeded the 5% year-on-year increase forecast at the end of March.
Alibaba Health's Fiscal Year 2024 Profit, Revenue Rise; Shares Rise 13%
Alibaba Health Information Technology's (HKG:0241) attributable profit rose to 883.5 million yuan, or 0.0627 yuan per share, in the year ended March 31, from 535.7 million yuan, or 0.0396 yuan per sha
Trending Industry Today: ALI HEALTH Leads Gains In Digital Health Stocks
May 28th - The industry of $Digital Health(LIST1251.HK)$ is trending higher today with 4 constituents up and ALI HEALTH leading Gains.$ALI HEALTH(00241.HK)$ rises 11.72% to HK$3.43 with a turnover of
SciNet shares, Pusheng Ali Health (00241), rose 12.05%, and UBS's views on Chinese stocks turned positive, favoring Technet stocks, etc.
Jinwu Financial News | SciNet stocks rose 12.05%, JD Health (06618) rose 5.15%, Shell (02423) rose 2.5%, Baidu (09888) rose 1.22%, followed by Tencent (00700), Bilili (09626), and Alibaba (09988).
Analysis
Price Target
No Data
